Gonorrhea testing and treatment in NYC and Long Island

Gonorrhea treatment starts with the infection site, symptoms and any complications. Urogenital, throat and rectal infections do not share every treatment option. Many people have no symptoms, so a partner’s diagnosis or screening result can still require care. New oral medicines add choices for eligible uncomplicated urogenital infection, while ceftriaxone remains the standard regimen in the current CDC guideline. Your plan should also cover other infections, partners and follow-up.

People with a positive result, a diagnosed partner exposure or compatible symptoms need clinical assessment. Tell the clinician about oral and anal exposures so throat and rectal infections are not missed. Blujepa’s gonorrhea label applies from age 12 and 45 kg, with limited or no alternatives; Nuzolvence applies from age 12 and 35 kg. Both approvals are for uncomplicated urogenital disease. A younger child, pregnancy, pelvic inflammatory disease, epididymitis or disseminated infection needs an appropriate separate pathway.

Bring the complete laboratory report rather than only a notification. The clinician reviews sampled sites, prior treatment and partner information and checks for complications.

Current CDC guidance uses ceftriaxone injection as standard treatment. The December 2025 oral approvals have product-specific eligibility and safety checks. Approval is not a reason to use an oral drug for an unlabeled site or ignore interactions.

If chlamydia has not been excluded, the clinician determines whether additional treatment is needed. HIV, syphilis and other testing may be appropriate. Discuss pregnancy prevention, vaccination and HIV prevention based on your situation.

Sex partners need evaluation and treatment. Avoid sex for seven days after treatment and until partners have been treated and symptoms have resolved. Get a written retesting and symptom-contact plan.

CDC recommends test of cure 7–14 days after treatment for pharyngeal gonorrhea. Routine test of cure is not needed for uncomplicated urogenital or rectal infections treated with recommended regimens, but new-drug or other clinical circumstances may require a specific plan. Retesting about three months later looks for reinfection and serves a different purpose. Ask which test you need and when.

Nuzolvence's US indication is uncomplicated urogenital gonorrhea in eligible patients. It is not an approved substitute for chlamydia or Mycoplasma genitalium treatment. If another infection is detected, the clinician chooses its separate regimen and follow-up. Do not assume one oral packet treats every positive STI site or organism.

Blujepa is the oral antibiotic gepotidacin. Its uncomplicated urinary tract infection indication applies to eligible female patients; it is not a general remedy for every urinary symptom. Burning, urgency or frequent urination can come from a UTI, an STI or another condition. An evaluation establishes the diagnosis and whether this antibiotic is appropriate. Choosing a recently approved medicine does not remove the need to assess infection location, other treatments and safety.

For uncomplicated UTI, the US label covers female adults and adolescents aged 12 or older weighing at least 40 kg, with infection caused by the specified susceptible organisms. The gonorrhea indication begins at 45 kg and is limited to uncomplicated urogenital infection in patients with limited or no alternative options. Fever, flank pain, vomiting, pregnancy or systemic illness may change the diagnosis and treatment setting. A clinician reviews kidney and liver function, heart-rhythm risks and interacting medicines before prescribing.

Tell the clinician when symptoms began, whether there is fever, back or flank pain, discharge, pregnancy possibility or a recent sexual exposure. Bring prior urine cultures, antibiotic courses and information about resistance or allergies.

Urine tests and sometimes a culture help guide UTI care. STI testing may require a separate urine or swab specimen. A standard urine culture is not a substitute for a chlamydia/gonorrhea NAAT.

The review includes QT prolongation, heart rhythm, potassium, renal/hepatic status and the full drug list. Some interactions or organ impairment make Blujepa inappropriate. The higher gonorrhea regimen has additional restrictions, so safety rules cannot be borrowed between indications.

The labeled UTI course is oral treatment twice daily for five days with food. Your prescription supplies the actual dose and instructions. Arrange review if symptoms persist or return, and a plan to act on any culture result.

Feeling better early does not justify stopping the course without advice. A missed dose, vomiting after a dose or inability to obtain the full prescription needs pharmacist or clinician guidance; do not double a dose. Persistent symptoms may require culture review, examination or a different diagnosis. Repeated infections deserve a separate assessment rather than repeated assumptions that this medicine is the right preventive treatment.

Do not assume the medicine, laboratory work, administration, monitoring or follow-up is included in the evaluation fee. Ask for an itemized estimate and identify which charges go to the clinic, pharmacy or laboratory. An approved appointment benefit and an approved medication benefit can be separate decisions.

Do not rely on symptoms disappearing or wait for gonorrhea to clear on its own. Infection can be present without symptoms, continue to spread and cause complications such as pelvic inflammatory disease. There is no safe untreated duration to recommend. A positive result or a partner’s diagnosis needs prompt clinician assessment and the appropriate antibiotic for the infection site. A urine result does not rule out throat or rectal infection. Severe pelvic or testicular pain, fever, eye symptoms or a painful swollen joint needs urgent care. Preventive doxy-PEP or leftover antibiotics are not a treatment plan.

Yes. Successful treatment does not provide immunity, and reinfection can occur from an untreated or newly infected partner. CDC reports that most repeat infections after treatment reflect reinfection, rather than antibiotic failure. Persistent symptoms or a positive follow-up test still need assessment. The clinician may request culture and susceptibility testing if failure is suspected. Do not assume it is harmless or repeat old antibiotics yourself. Arrange partner care and retesting about three months after treatment. Throat infection has a separate test-of-cure plan 7–14 days after treatment.

Improvement depends on the site, complications and whether the treatment was appropriate. Symptoms alone cannot prove cure. Contact the clinician if symptoms do not resolve within 3–5 days after recommended treatment. With no sexual contact during follow-up, CDC treats this as possible treatment failure. Reinfection or another condition can also explain symptoms. Contact the treating clinician instead of waiting indefinitely or adding antibiotics. Avoid sex for seven days after treatment and until partners have been treated and symptoms have resolved. Keep any scheduled throat cure test and later reinfection test.

A negative urine result does not rule out throat gonorrhea. The samples assess different sites. Results collected before and after antibiotics also need context. Certain throat NAATs may react with other Neisseria species. That assay-specific possibility does not prove your result is false. Ask the clinician to review the named assay, sample sites, dates and antibiotics, and whether culture or another validated test is needed. Keep the throat test-of-cure plan 7–14 days after treatment. For a positive post-treatment throat NAAT, CDC advises efforts to confirm it with culture before retreatment. Results alone cannot reliably date infection or establish a partner’s behavior.